Body's own cell-to-cell messaging packets studied as the basis for next-generation medicines
Researchers are investigating extracellular vesicles (EVs), which are cell-to-cell messaging packets, as a potential foundation for next-generation regenerative medicines. The study aims to develop methods for the large-scale manufacturing of these nanoparticles to treat conditions like cancer and inflammation.
Why it matters
Advancements in EV technology could revolutionize regenerative medicine and provide new therapeutic pathways for currently difficult-to-treat diseases.
by Germans Trias i Pujol Research Institute
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Graphical Abstract. Credit: Journal of Extracellular Vesicles (2026). DOI: 10.1002/jev2.70330 The Blood and Tissue Bank is studying how to therapeutically manufacture and use a type of nanoparticles released by the body's cells to communicate with one another, in one of the most promising fields of research for the therapies of the future. New medicines and advanced therapies modify cells (immune cells), genes and tissues to treat diseases such as cancer. However, the next step is to focus on these subcellular packages loaded with biological information, known as extracellular vesicles (EVs), which perform essential functions such as tissue regeneration and the modulation of inflammation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in